Signaturefd LLC Sells 4,430 Shares of Genmab A/S (NASDAQ:GMAB)

Signaturefd LLC reduced its position in shares of Genmab A/S (NASDAQ:GMAB) by 26.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,537 shares of the company’s stock after selling 4,430 shares during the period. Signaturefd LLC’s holdings in Genmab A/S were worth $399,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Grandfield & Dodd LLC lifted its holdings in Genmab A/S by 2.3% during the 4th quarter. Grandfield & Dodd LLC now owns 25,558 shares of the company’s stock valued at $814,000 after purchasing an additional 565 shares during the last quarter. Knights of Columbus Asset Advisors LLC lifted its holdings in Genmab A/S by 17.9% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 6,732 shares of the company’s stock valued at $214,000 after purchasing an additional 1,020 shares during the last quarter. NewEdge Wealth LLC raised its stake in shares of Genmab A/S by 50.7% in the fourth quarter. NewEdge Wealth LLC now owns 119,989 shares of the company’s stock worth $3,820,000 after acquiring an additional 40,382 shares during the last quarter. Cerity Partners LLC raised its stake in shares of Genmab A/S by 344.3% in the fourth quarter. Cerity Partners LLC now owns 55,053 shares of the company’s stock worth $1,753,000 after acquiring an additional 42,661 shares during the last quarter. Finally, Custom Index Systems LLC bought a new position in shares of Genmab A/S in the fourth quarter worth about $410,000. 7.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on GMAB. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $46.00 to $48.00 in a research note on Friday, February 23rd. Citigroup downgraded shares of Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, April 4th. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Tuesday, March 26th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $48.50.

Genmab A/S Price Performance

GMAB opened at $27.46 on Friday. The company has a market cap of $18.16 billion, a price-to-earnings ratio of 28.60, a price-to-earnings-growth ratio of 2.04 and a beta of 0.99. The firm has a 50 day simple moving average of $29.45 and a 200 day simple moving average of $30.12. Genmab A/S has a fifty-two week low of $26.32 and a fifty-two week high of $42.72.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. The firm had revenue of $675.29 million during the quarter, compared to analysts’ expectations of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. As a group, analysts expect that Genmab A/S will post 1.06 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.